DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» Danoprevir
Danoprevir
Twelve-Week Ravidasvir Plus Ritonavir-Boosted Danoprevir And
Review Resistance to Mericitabine, a Nucleoside Analogue Inhibitor of HCV RNA-Dependent RNA Polymerase
Global Eradication of Hepatitis C Virus: a Herculean Task Rajinder M Joshi* Nuclear Medicine and Laboratory Center, Yiaco Medical Co
First Clinical Study Using HCV Protease Inhibitor Danoprevir to Treat Naïve and Experienced COVID-19 Patients
ABT-450/R (Abbott) – GS-9451 (Gilead) • Second Generation (Pan-Genotype, High Barrier to Resistance) – MK-5172 (Merck) – ACH-2684 (Achillion)
Targeting Drug Resistance in HCV NS3/4A Protease: Mechanisms and Inhibitor Design Strategies
Interferon-Combination Strategies for the Treatment of Chronic Hepatitis C
Ritonavir-Boosted Danoprevir Plus Peginterferon Alfa-2A and Ribavirin in Asian Chronic Hepatitis C Patients with Or Without Cirr
HIV/HCV Coinfection
Identification of Existing Pharmaceuticals and Herbal Medicines As Inhibitors of SARS-Cov-2 Infection
The Importance of Studying Drug Transporters in HCV Drug Development
What Is the Minimum Cost Per Person to Cure HCV?
COVID-19 Issues Issue 3
Medical Product Quality Report – COVID-19 Issues
The Molecular Basis of Drug Resistance Against Hepatitis C Virus NS3/4A Protease Inhibitors
Broad-Spectrum Inhibition of Coronavirus Main and Papain-Like Proteases by HCV Drugs
Antiviral Activity, Safety, and Pharmacokinetics of Danoprevir/Ritonavir Plus PEG-IFN Α-2A/RBV in Hepatitis C Patients
Hepatitis C Virus Protease Inhibitors Show Differential Efficacy and Interactions with Remdesivir for Treatment of SARS-Cov-2 in Vitro
Top View
Hepatitis C Virus
Emerging Therapeutic Options in Hepatitis C Virus Infection
In Silico Evaluation of the Effectivity of Approved Protease Inhibitors
201917Orig1s000
First Clinical Study Using HCV Protease Inhibitor Danoprevir to Treat Naïve and Experienced COVID-19 Patients
Efficacy and Safety of 12-Week Interferon-Based Danoprevir Regimen in Patients with Genotype 1 Chronic Hepatitis C
Hold the Interferon: Hcv Treatment in the Era of Direct Acting Antivirals
Efficacy and Safety of 12-Week Interferon-Based Danoprevir Regimen in Patients with Genotype 1 Chronic Hepatitis C
Evaluation of 19 Antiviral Drugs Against SARS-Cov-2 Infection
Download Product Insert (PDF)
A Randomized Trial of Mericitabine Plus Peginterferon Alfa2a/Ribavirin for 24 Weeks in Treatmentnaive HCV Genotype 1/4 Pa
Remdesivir from Wikipedia, the Free Encyclopedia
Distal Mutation V36M Allosterically Modulates the Active Site to Accentuate Drug Resistance in HCV NS3/4A
Interferon-Based Combination Treatment for Chronic Hepatitis C in the Era of Direct Acting Antivirals
Antiviral Agents Approved for the Treatment of Chronic HBV Infection
Quantifying Antiviral Activity Optimizes Drug Combinations Against Hepatitis C Virus Infection
Glecaprevir/Pibrentasvir X 8 Wks
Future Perspectives in the Treatment of Chronic Hepatitis C
Does the Choice of the Interferon Interfere with the SVR Response
Synergy of Entry Inhibitors with Direct-Acting Antivirals Uncovers Novel Combinations for Prevention and Treatment of Hepatitis
Hepatitis C Virus: Structural Insights Into Protease Inhibitor Efficacy and Drug Resistance: a Dissertation
A 3-Year Follow-Up Study After Treatment with Simeprevir in Combination with Pegylated Interferon-Α and Ribavirin for Chronic H
Danoprevir | Medchemexpress
Antiviral Drugs Prioritization for COVID-19 Management Based on Rational Selection
209195Orig1s000
Simeprevir Suppresses SARS-Cov-2 Replication and Synergizes with Remdesivir
Danoprevir for the Treatment of Hepatitis C Virus Infection: Design, Development, and Place in Therapy
Paritaprevir/Ombitasvir/Dasabuvir